110 related articles for article (PubMed ID: 22212074)
1. Prostate cancer: towards the standardization and synthesis of morphology, genetics, and prognosis.
Berney D; Cheng L
Histopathology; 2012 Jan; 60(1):1-3. PubMed ID: 22212074
[TBL] [Abstract][Full Text] [Related]
2. [Markers for diagnosis, prediction and prognosis of prostate cancer].
Taskén KA; Angelsen A; Svindland A; Eide T; Berge V; Wahlquist R; Karlsen S
Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3279-82. PubMed ID: 16327854
[TBL] [Abstract][Full Text] [Related]
3. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
[TBL] [Abstract][Full Text] [Related]
4. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive factors in prostate cancer: historical perspectives and recent international consensus initiatives.
Srigley JR; Amin M; Boccon-Gibod L; Egevad L; Epstein JI; Humphrey PA; Mikuz G; Newling D; Nilsson S; Sakr W; Wheeler TM; Montironi R
Scand J Urol Nephrol Suppl; 2005 May; (216):8-19. PubMed ID: 16019756
[TBL] [Abstract][Full Text] [Related]
6. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Prostate Cancer Working Group.
Grignon DJ; Hammond EH
Arch Pathol Lab Med; 1995 Dec; 119(12):1122-6. PubMed ID: 7503660
[TBL] [Abstract][Full Text] [Related]
7. Re: Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?
Ansari MS
J Urol; 2002 Jul; 168(1):200; author reply 200-1. PubMed ID: 12050532
[No Abstract] [Full Text] [Related]
8. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen.
Fradet Y
Curr Opin Urol; 2009 May; 19(3):243-6. PubMed ID: 19325493
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
11. Applications of immunohistochemistry to the diagnosis and prognostication of prostate carcinoma and prostatic intraepithelial neoplasia.
Maygarden SJ
Pathol Annu; 1994; 29 Pt 1():303-20. PubMed ID: 7510385
[No Abstract] [Full Text] [Related]
12. The role of tissue microarrays in prostate cancer biomarker discovery.
Datta MW; True LD; Nelson PS; Amin MB
Adv Anat Pathol; 2007 Nov; 14(6):408-18. PubMed ID: 18049130
[TBL] [Abstract][Full Text] [Related]
13. [Diagnostic value of tissue and serum prostate specific antigen in prostate cancer].
Medvedev VL
Voen Med Zh; 2004 Feb; 325(2):50-4. PubMed ID: 15101295
[No Abstract] [Full Text] [Related]
14. [The influence of prostate volume on the diagnostic parameters related to PSA and clinicopathological features of prostate cancer].
Kimura G; Kimata R; Saito Y; Yoshida K; Nishimura T
Nihon Rinsho; 2002 Dec; 60 Suppl 11():479-85. PubMed ID: 12599623
[No Abstract] [Full Text] [Related]
15. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.
Salagierski M; Schalken JA
J Urol; 2012 Mar; 187(3):795-801. PubMed ID: 22245323
[TBL] [Abstract][Full Text] [Related]
16. Anatomy of the prostate revisited: implications for prostate biopsy and zonal origins of prostate cancer.
Fine SW; Reuter VE
Histopathology; 2012 Jan; 60(1):142-52. PubMed ID: 22212083
[TBL] [Abstract][Full Text] [Related]
17. New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era.
Bickers B; Aukim-Hastie C
Anticancer Res; 2009 Aug; 29(8):3289-98. PubMed ID: 19661347
[TBL] [Abstract][Full Text] [Related]
18. From gene to clinic: TMA-based clinical validation of molecular markers in prostate cancer.
Schlomm T; Chun FKh; Erbersdobler A
Methods Mol Biol; 2010; 664():177-89. PubMed ID: 20690063
[TBL] [Abstract][Full Text] [Related]
19. Telomerase expression as a marker in prostate cancer: correlation to clinicopathologic predictors.
Athanassiadou P; Bantis A; Gonidi M; Liossi A; Aggelonidou E; Petrakakou E; Giannopoulos A
J Exp Clin Cancer Res; 2003 Dec; 22(4):613-8. PubMed ID: 15053304
[TBL] [Abstract][Full Text] [Related]
20. Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Murphy GP; Busch C; Abrahamsson PA; Epstein JI; McNeal JE; Miller GJ; Mostofi FK; Nagle RB; Nordling S; Parkinson C
Scand J Urol Nephrol Suppl; 1994; 162():7-42; discussion 115-27. PubMed ID: 7817162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]